Skip to main content

Table 1 Variations of tumor size during treatment according to RECIST version 1.1

From: Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report

Date

Exposure

Duration

Target lesions in lung (LD×SD, millimeter)

Target lesions in brain (LD×SD, millimeter)

2015.04

Baseline

N/A

35 × 24

6.5 × 4.2

2015.06

AP

2 cycles

48 × 42

5.1 × 4.0

2015.07

Icotinib

1 month

22 × 17

2.3 × 2.1

2015.09

Icotinib

3 months

21 × 18

2.0 × 1.8

2015.12

Icotinib

6 months

23 × 21

0

2016.02

Icotinib

8 months

29 × 26

0

2016.04

AZD9291

1 month

17 × 15

N/A

2016.06

AZD9291

3 months

18 × 17

N/A

2016.09

AZD9291

6 months

20 × 16

N/A

2017.01

AZD9291

10 months

61 × 48

0

2017.03

Docetaxel

2 cycles

88 × 39

Multiple lesions

2017.05

Icotinib

2 months

90 × 49

0

2017.06

Icotinib

3 months

64 × 28

N/A

2017.09

Icotinib

6 months

71 × 38

7.1 × 4.2, 3.4 × 2.2

2017.11

Icotinib

8 months

78 × 53

9.5 × 7.1, 6.0 × 5.3

2017.12

WBRT

15F

N/A

N/A

2018.02

AZD9291

1 month

58 × 43

3.0 × 2.1, 0

  1. Abbreviations: LD Longest Diameter, SD Shortest Diameter, N/A Not/Applicable, AP Pemetrexed + Cisplatin, WBRT Whole Brain Radiation Therapy